Market Closed -
Nyse
04:10:00 2024-06-04 pm EDT
|
5-day change
|
1st Jan Change
|
0.7016
USD
|
+16.16%
|
|
+15.41%
|
-24.56%
|
Fiscal Period: June |
2018
|
2019
|
2020
|
2021
|
2022
|
2023
|
---|
Capitalization
1 |
9.568
|
10.27
|
6.175
|
23.67
|
6.956
|
6.399
|
Enterprise Value (EV)
1 |
9.17
|
5.492
|
-0.6791
|
18.04
|
1.425
|
2.996
|
P/E ratio
|
-6.6
x
|
-5.97
x
|
-5.46
x
|
3.48
x
|
-3.43
x
|
-3.5
x
|
Yield
|
-
|
-
|
-
|
-
|
-
|
-
|
Capitalization / Revenue
|
0.18
x
|
0.23
x
|
0.13
x
|
0.58
x
|
0.17
x
|
0.13
x
|
EV / Revenue
|
0.18
x
|
0.12
x
|
-0.01
x
|
0.44
x
|
0.03
x
|
0.06
x
|
EV / EBITDA
|
-67.4
x
|
-12
x
|
-0.61
x
|
5.58
x
|
-0.19
x
|
-5.38
x
|
EV / FCF
|
-14,672
x
|
8.36
x
|
-0.16
x
|
-2.69
x
|
-0.34
x
|
-1.31
x
|
FCF Yield
|
-0.01%
|
12%
|
-636%
|
-37.2%
|
-297%
|
-76.5%
|
Price to Book
|
0.55
x
|
0.68
x
|
0.45
x
|
1.14
x
|
0.36
x
|
0.37
x
|
Nbr of stocks (in thousands)
|
7,417
|
6,987
|
6,899
|
6,920
|
6,954
|
7,032
|
Reference price
2 |
1.290
|
1.470
|
0.8950
|
3.420
|
1.000
|
0.9100
|
Announcement Date
|
9/25/18
|
9/27/19
|
9/29/20
|
9/27/21
|
9/28/22
|
9/28/23
|
Fiscal Period: June |
2018
|
2019
|
2020
|
2021
|
2022
|
2023
|
---|
Net sales
1 |
52.17
|
45.62
|
47.81
|
40.68
|
41.34
|
47.95
|
EBITDA
1 |
-0.136
|
-0.457
|
1.121
|
3.232
|
-7.383
|
-0.557
|
EBIT
1 |
-1.994
|
-2.185
|
-0.329
|
1.871
|
-8.926
|
-2.322
|
Operating Margin
|
-3.82%
|
-4.79%
|
-0.69%
|
4.6%
|
-21.59%
|
-4.84%
|
Earnings before Tax (EBT)
1 |
-1.478
|
-2.078
|
-0.29
|
7
|
-1.615
|
-1.662
|
Net income
1 |
-1.593
|
-1.754
|
-1.14
|
6.89
|
-2.009
|
-1.795
|
Net margin
|
-3.05%
|
-3.84%
|
-2.38%
|
16.93%
|
-4.86%
|
-3.74%
|
EPS
2 |
-0.1955
|
-0.2461
|
-0.1639
|
0.9833
|
-0.2913
|
-0.2599
|
Free Cash Flow
1 |
-0.000625
|
0.6568
|
4.322
|
-6.719
|
-4.231
|
-2.292
|
FCF margin
|
-0%
|
1.44%
|
9.04%
|
-16.51%
|
-10.23%
|
-4.78%
|
FCF Conversion (EBITDA)
|
-
|
-
|
385.57%
|
-
|
-
|
-
|
FCF Conversion (Net income)
|
-
|
-
|
-
|
-
|
-
|
-
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
9/25/18
|
9/27/19
|
9/29/20
|
9/27/21
|
9/28/22
|
9/28/23
|
Fiscal Period: June |
2018
|
2019
|
2020
|
2021
|
2022
|
2023
|
---|
Net Debt
1 |
-
|
-
|
-
|
-
|
-
|
-
|
Net Cash position
1 |
0.4
|
4.78
|
6.85
|
5.62
|
5.53
|
3.4
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
Free Cash Flow
1 |
-0
|
0.66
|
4.32
|
-6.72
|
-4.23
|
-2.29
|
ROE (net income / shareholders' equity)
|
-5.83%
|
-12.4%
|
-4.07%
|
40.2%
|
-8.63%
|
-9.06%
|
ROA (Net income/ Total Assets)
|
-4.05%
|
-5.4%
|
-0.78%
|
3.93%
|
-18.7%
|
-5.67%
|
Assets
1 |
39.31
|
32.49
|
145.2
|
175.4
|
10.71
|
31.67
|
Book Value Per Share
2 |
2.340
|
2.150
|
1.990
|
3.010
|
2.750
|
2.480
|
Cash Flow per Share
2 |
0.4700
|
1.110
|
1.620
|
1.440
|
0.9800
|
0.6400
|
Capex
1 |
1.86
|
1.27
|
1.19
|
2.6
|
3.19
|
2
|
Capex / Sales
|
3.57%
|
2.79%
|
2.48%
|
6.38%
|
7.72%
|
4.17%
|
Announcement Date
|
9/25/18
|
9/27/19
|
9/29/20
|
9/27/21
|
9/28/22
|
9/28/23
|
|
1st Jan change
|
Capi.
|
---|
| -24.56% | 4.94M | | -38.30% | 13.9B | | -32.86% | 10.68B | | +11.56% | 6.24B | | -11.61% | 5.96B | | +73.30% | 4.72B | | -4.38% | 4.56B | | -6.67% | 3.87B | | -19.00% | 3.17B | | -13.44% | 2.86B |
Other Drug Retailers
|